A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Start Date
3/19/2026
Completion Date
7/31/2029
Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Oral Brepocitinib
Placebo
Conditions
Locations
Clinical Trial Site
Birmingham, Alabama 35244
United States
Clinical Trial Site
Phoenix, Arizona 85006
United States
Clinical Trial Site
Scottsdale, Arizona 85259
United States
Clinical Trial Site
Irvine, California 92617
United States
Clinical Trial Site
Oakland, California 94611
United States
Clinical Trial Site
Sacramento, California 95823
United States
Clinical Trial Site
San Francisco, California 94115
United States
Clinical Trial Site
Denver, Colorado 80237
United States
Clinical Trial Site
Farmington, Connecticut 06032
United States
Clinical Trial Site
New Haven, Connecticut 06519
United States
Clinical Trial Site
Miami, Florida 33136
United States
Clinical Trial Site
Chicago, Illinois 60611
United States
Clinical Trial Site
Skokie, Illinois 60077
United States
Clinical Trial Site
Clarksville, Indiana 47129
United States
Clinical Trial Site
Indianapolis, Indiana 46250
United States
Clinical Trial Site
Leawood, Kansas 66211
United States
Clinical Trial Site
Louisville, Kentucky 40241
United States
Clinical Trial Site
Boston, Massachusetts 02115
United States
Clinical Trial Site
Burlington, Massachusetts 01805
United States
Clinical Trial Site
Ann Arbor, Michigan 48103
United States
Clinical Trial Site
Ann Arbor, Michigan 48109
United States
Clinical Trial Site
Medina, Minnesota 55340
United States
Clinical Trial Site
Minneapolis, Minnesota 55455
United States
Clinical Trial Site
Kansas City, Missouri 66103
United States
Clinical Trial Site
Lee's Summit, Missouri 64064
United States
Clinical Trial Site
Lebanon, New Hampshire 03766
United States
Clinical Trial Site
New Hyde Park, New York 11042
United States
Clinical Trial Site
New York, New York 10451
United States
Clinical Trial Site
Durham, North Carolina 27713
United States
Clinical Trial Site
Cleveland, Ohio 44195
United States
Clinical Trial Site
Columbus, Ohio 43213
United States
Clinical Trial Site
Medina, Ohio 44256
United States
Clinical Trial Site
Portland, Oregon 97210
United States
Clinical Trial Site
Philadelphia, Pennsylvania 19104
United States
Clinical Trial Site
Charleston, South Carolina 29425
United States
Clinical Trial Site
Murfreesboro, Tennessee 37128
United States
Clinical Trial Site
Smyrna, Tennessee 37167
United States
Clinical Trial Site
Austin, Texas 78613
United States
Clinical Trial Site
Austin, Texas 78660
United States
Clinical Trial Site
Cedar Park, Texas 78613
United States
Clinical Trial Site
Prosper, Texas 75078
United States
Clinical Trial Site
Tyler, Texas 75703
United States
Clinical Trial Site
Murray, Utah 84107
United States
Clinical Trial Site
Norfolk, Virginia 23502
United States
Clinical Trial Site
Richmond, Virginia 23235
United States
Clinical Trial Site
Roanoke, Virginia 24016
United States
Clinical Trial Site
Mill Creek, Washington 98012
United States
Clinical Trial Site
Adelaide, 5074
Australia
Clinical Trial Site
Perth, 6018
Australia
Clinical Trial Site
Sydney, 2217
Australia
Clinical Trial Site
Edmonton, Alberta T6G1C3
Canada
Clinical Trial Site
Guelph, Ontario N1L0B7
Canada
Clinical Trial Site
London, Ontario M5M3Z8
Canada
Clinical Trial Site
Toronto, Ontario L4B1A5
Canada
Clinical Trial Site
Toronto, Ontario N6H5L4
Canada
Clinical Trial Site
Salford, Manchester M68HD
United Kingdom
Clinical Trial Site
Glasgow, Scotland G312ER
United Kingdom
Clinical Trial Site
Brighton, BN21ES
United Kingdom
Clinical Trial Site
London, SE19RT
United Kingdom
Clinical Trial Site
London, SW109NH
United Kingdom
Clinical Trial Site
Wrexham, LL7YP
United Kingdom